Aspira Pathlab & Diagnostics Ltd
Incorporated in 1973, Aspira Pathlab & Diagnostics Ltd is in the business of pathology and related healthcare services[1]
- Market Cap ₹ 63.9 Cr.
- Current Price ₹ 62.0
- High / Low ₹ 107 / 44.0
- Stock P/E 26.6
- Book Value ₹ 7.02
- Dividend Yield 0.00 %
- ROCE 17.0 %
- ROE 33.0 %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 50.5 to 39.0 days.
- Company's working capital requirements have reduced from 19.6 days to 14.1 days
Cons
- Stock is trading at 8.83 times its book value
- Promoter holding is low: 18.4%
- Company might be capitalizing the interest cost
- Promoter holding has decreased over last 3 years: -17.8%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|
13.20 | 22.00 | 22.62 | |
14.38 | 18.49 | 19.15 | |
Operating Profit | -1.18 | 3.51 | 3.47 |
OPM % | -8.94% | 15.95% | 15.34% |
0.42 | 0.36 | 0.41 | |
Interest | 0.37 | 0.35 | 0.00 |
Depreciation | 1.54 | 1.49 | 1.49 |
Profit before tax | -2.67 | 2.03 | 2.39 |
Tax % | 0.00% | 0.00% | |
-2.67 | 2.02 | 2.40 | |
EPS in Rs | -2.59 | 1.96 | 2.33 |
Dividend Payout % | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 67% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 177% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 25% |
3 Years: | 13% |
1 Year: | 37% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 33% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2024 | Mar 2025 | |
---|---|---|
Equity Capital | 10.29 | 10.29 |
Reserves | -5.08 | -3.06 |
7.71 | 8.13 | |
1.79 | 2.11 | |
Total Liabilities | 14.71 | 17.47 |
6.79 | 6.53 | |
CWIP | 0.00 | 0.00 |
Investments | 0.00 | 0.08 |
7.92 | 10.86 | |
Total Assets | 14.71 | 17.47 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2024 | Mar 2025 | |
---|---|---|
1.05 | 1.83 | |
0.14 | 0.12 | |
-0.95 | -0.99 | |
Net Cash Flow | 0.24 | 0.95 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2024 | Mar 2025 | |
---|---|---|
Debtor Days | 61.94 | 38.99 |
Inventory Days | 62.69 | 50.31 |
Days Payable | 101.70 | 73.00 |
Cash Conversion Cycle | 22.93 | 16.30 |
Working Capital Days | 25.16 | 14.10 |
ROCE % | 17.04% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
7 Oct - Compliance Certificate under reg 74 (5) of SEBI (DP) regulation, 2018 for the quarter ended September 30, 2025
-
Disclosure Regarding Detailed Public Statement ("DPS") In Relation To The Open Offer To The Public Shareholders
6 Oct - DPS dated October 06, 2025: open offer for Aspira Pathlab & Diagnostics by five acquirers; newspaper publications enclosed.
-
Detailed Public Statement
6 Oct - Aftertrade Broking Pvt Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Detailed Public Statement As per Regulations 13(4), 14(3) and …
-
Announcement under Regulation 30 (LODR)-Cessation
27 Sep - Mrs. Mangala Prabhu ceases as Independent Director and committee chair effective September 27, 2025.
-
Announcement under Regulation 30 (LODR)-Public Announcement-Open Offer
26 Sep - Open Offer dated Sep 26, 2025 to buy 26,76,180 shares (26%) at Rs.55
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
Company is in the business of running, owning, managing and administering Diagnostics Centers in Mumbai